Despite Diagnostic Challenges, ADCs Are Poised to Expand Treatment Options in Lung Cancer
As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.
Source: onclive.com